FIGURE 8.

NI-1201 abrogates more efficiently IL-6 trans-signaling activity in conditions of exacerbated IL-6 compared with tocilizumab. A, Ba/F3-hgp130-hIL-6R cells were stimulated with increasing concentrations of hIL-6 and 10 nm NI-1201 or tocilizumab. After 72 h, cell proliferation was measured. Data are expressed as the mean ± S.E. B–D, Ba/F3-hgp130 cells were stimulated with increasing hIL-6 concentrations and a fixed shIL-6R concentration (10 ng/ml) at the indicated molar ratios. After 72 h, cell proliferation was measured in the presence or absence of varying concentrations of NI-1201, tocilizumab, or isotype control. Data are expressed as the mean ± S.E. (error bars). TCZ, tocilizumab.